1. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?
- Author
-
Bazyluk, Angelika, Malyszko, Jolanta, and Zbroch, Edyta
- Subjects
KIDNEY diseases ,CARDIOVASCULAR diseases ,MORTALITY ,KIDNEY function tests ,HYPOGLYCEMIC agents ,ADIPOSE tissues ,AGING ,BLOOD pressure ,BLOOD sugar ,CHRONIC kidney failure ,DIABETES ,DIABETIC nephropathies ,DIET ,EXERCISE ,HEMODYNAMICS ,HYPERLIPIDEMIA ,SMOKING ,DISEASE progression ,ALLOPURINOL ,PREVENTION - Abstract
The prevalence of chronic kidney disease (CKD) has increased markedly over past decades due to the aging of the worldwide population. Despite the progress in the prevention and treatment, the cardiovascular (CV) morbidity and mortality remain high among patients with CKD. Although CKD is a progressive and irreversible condition, it is possible to slow decreasing kidney function, as well as the development and progression of associated with kidney disease comorbidities. Diabetes mellitus has become major cause of CKD worldwide. It is estimated that the prevalence of diabetes will increase from 425 million worldwide in 2017 to 629 million by 2045, substantially the percentage of diabetic nephropathy among CKD patients is set to rise markedly. The results of multicenter trials concerning novel antidiabetic drugs suggest that efficacy in reducing CV risk is independent of the improvement in glycemic control. This review discusses underlying causes of high CV risk and strategies reducing individual burden among CKD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF